INVO Bioscience Enters Material Agreement, Incurs Financial Obligation
Ticker: IVF · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1417926
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
INVO Bio entered a big deal Sept 25, now has new debt.
AI Summary
INVO Bioscience, Inc. entered into a Material Definitive Agreement on September 25, 2024, which also created a direct financial obligation for the registrant. The filing details this agreement and related financial obligations, with further information provided in the accompanying exhibits.
Why It Matters
This filing indicates a significant new financial commitment or agreement for INVO Bioscience, which could impact its financial health and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and incurring financial obligations can introduce financial risks and operational changes for a company.
Key Players & Entities
- INVO Bioscience, Inc. (company) — Registrant
- September 25, 2024 (date) — Date of earliest event reported
FAQ
What type of Material Definitive Agreement did INVO Bioscience, Inc. enter into?
The filing indicates the entry into a Material Definitive Agreement but does not specify the exact nature of the agreement in the provided text.
What is the nature of the direct financial obligation incurred by INVO Bioscience, Inc.?
The filing states that a direct financial obligation was created, but the specific details of this obligation are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 25, 2024.
What is the state of incorporation for INVO Bioscience, Inc.?
INVO Bioscience, Inc. is incorporated in Nevada.
What is the principal executive office address for INVO Bioscience, Inc.?
The principal executive office address for INVO Bioscience, Inc. is 5582 Broadcast Court, Sarasota, FL 34240.
Filing Stats: 627 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-01 17:26:10
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value INVO The Nasdaq Stock Mar
- $384,250 — Buyer") under which the Buyer purchased $384,250 of the Company's future sales for a gro
- $265,000 — ure sales for a gross purchase price of $265,000 (the "Transaction"). The Company receiv
- $251,750 — ). The Company received net proceeds of $251,750. Until the purchase price has been repa
- $9,606 — id, the Company agreed to pay the Buyer $9,606 per week. The Company intends to use th
- $1,000,000 b — equity investments in the net amount of $1,000,000 by November 30, 2024. Decathlon, the Bu
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 10KB
- ex10-2.htm (EX-10.2) — 50KB
- ex10-3.htm (EX-10.3) — 53KB
- ex10-1_001.jpg (GRAPHIC) — 1357KB
- ex10-1_002.jpg (GRAPHIC) — 2153KB
- ex10-1_003.jpg (GRAPHIC) — 2093KB
- ex10-1_004.jpg (GRAPHIC) — 2157KB
- ex10-1_005.jpg (GRAPHIC) — 2067KB
- ex10-1_006.jpg (GRAPHIC) — 1673KB
- ex10-1_007.jpg (GRAPHIC) — 1839KB
- ex10-1_008.jpg (GRAPHIC) — 2192KB
- ex10-1_009.jpg (GRAPHIC) — 1947KB
- ex10-1_010.jpg (GRAPHIC) — 1791KB
- ex10-1_011.jpg (GRAPHIC) — 388KB
- ex10-1_012.jpg (GRAPHIC) — 678KB
- ex10-1_013.jpg (GRAPHIC) — 678KB
- 0001493152-24-039059.txt ( ) — 29276KB
- invo-20240925.xsd (EX-101.SCH) — 3KB
- invo-20240925_lab.xml (EX-101.LAB) — 33KB
- invo-20240925_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 25, 2024, INVO Bioscience, Inc. (the "Company") entered into a Standard Merchant Cash Advance Agreement (the "Agreement") with a buyer (the "Buyer") under which the Buyer purchased $384,250 of the Company's future sales for a gross purchase price of $265,000 (the "Transaction"). The Company received net proceeds of $251,750. Until the purchase price has been repaid, the Company agreed to pay the Buyer $9,606 per week. The Company intends to use the proceeds for working capital and general corporate purposes. The Company received approval from its senior secured lender, Decathlon Alpha V, L.P. ("Decathlon") to consummate the Transaction pursuant to an Amended and Restated First Amendment (the "Amendment") to Revenue Loan and Security Agreement, dated September 29, 2023 between the Company and Decathlon (the "Revenue Loan and Security Agreement"). Pursuant to the Amendment, the minimum interest multiples set forth in the Revenue Loan and Security Agreement will automatically increase by 0.15x as of December 1, 2024 if the Company does not receive equity investments in the net amount of $1,000,000 by November 30, 2024. Decathlon, the Buyer, and the Company also signed a subordination agreement in which the Buyer subordinated its rights under the transaction to those of Decathlon. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Exhibit 10.1 Standard Merchant Cash Advance Agreement 10.2 Amended and Restated First Amendment to Revenue Loan and Security Agreement 10.3 Subordination Agreement 104 Cover Page Interactive Data File (embedded within the XBRL document) -2-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 1, 2024 INVO BIOSCIENCE, INC. /s/ Steven Shum Steven Shum Chief Executive Officer -3-